Tracer library / [99mTc]N4-CCK-104

[99mTc]N4-CCK-104

Also written as [Tc-99m]Tc-N4-CCK-104

Radionuclide: Tc-99m t½ 360.6 min
Modality: SPECT
Production route: —
Stage: Preclinical
Syntheses indexed: 1

Preclinical only, no clinical indication yet

What it is

Compound class: N4 (tetraamine)-conjugated cholecystokinin-2 receptor (CCK-2R)-targeted peptide
Target / mechanism: Cholecystokinin-2 receptor (CCK-2R) PMID 42477299
Clinical application: SPECT imaging of CCK-2R-expressing malignancies PMID 42477299
Theranostic pair: —

Published syntheses

Module	Cassette	Purification	Yield %	RCP %	Precursor / supplier	Source
Manual synthesis	—	none	>99%	87.7-94.0%	N4-CCK-104	42477299 2026 EJNMMI Radiopharm Chem The labeling solution was incubated at 95 °C for 15 min. - 99mTc-Labeling afforded [99mTc]Tc-N4-CCK-66 and [99mTc]Tc-N4-CCK-100 to -105 ([99mTc]Tc-11 to -17) in quantitative radiochemical yields (RCY > 99%)

Need this precursor?We can point you to suppliers for [99mTc]N4-CCK-104, or handle the enquiry for you.

Get in touch

Notes

Added at stage 22: promoted from 'Reported once' (single-article, no diagnostic pair at discovery) because a full-text synthesis with extracted data exists in parsed-therapy.xlsx -- PMID(s): 42477299. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty. Compound class inferred from precursor name (not stated outright) -- PMID 42477299: '[99mTc]Tc-N4-CCK-104 ([99mTc]Tc-16)'. Stage set/updated at stage 23 from PMID 42477299: 'Synthesis and in vitro evaluation of pharmacokinetically optimized 99mTc-labeled cholecystokinin-2 receptor-targeted peptides for improved SPECT imaging.'. | Stage 30 (2026-09-18): Modality was 'Therapy' -- a bucket value given to every agent found by the therapy-oriented bulk search (stages 21-22), not a source statement. Corrected to SPECT: Tc-99m is a gamma emitter used only for SPECT imaging. Linked articles: PMID 42477299.